Publications by authors named "Hoentjen F"
Background: Novel colorectal cancer endoscopic surveillance techniques for inflammatory bowel disease (IBD) have recently been developed.
Aims: Compare the efficacy of currently available techniques for dysplasia detection in colonic IBD.
Methods: We conducted a systematic literature search from inception to March 2024 for randomized controlled trials (RCTs) or prospective cohort studies enrolling adults with IBD and having surveillance colonoscopy for dysplasia screening.
Background: It remains unclear if the increased colorectal neoplasia detection rate in inflammatory bowel disease (IBD) by high-definition (HD) dye-based chromoendoscopy compared with HD white-light endoscopy is due to enhanced contrast or increased inspection times. Longer withdrawal times may yield similar neoplasia detection rates as found by HD chromoendoscopy.
Objective: To compare colorectal neoplasia detection rates for HD white-light endoscopy with segmental re-inspection and HD chromoendoscopy, using single-pass HD white-light endoscopy as an additional control group.
Inflammatory bowel disease [IBD] patients are at increased risk of developing colorectal neoplasia [CRN]. In this review, we aim to provide an up-to-date overview and future perspectives on CRN management in IBD. Advances in endoscopic surveillance and resection techniques have resulted in a shift towards endoscopic management of neoplastic lesions in place of surgery.
View Article and Find Full Text PDFArticle Synopsis
- In the LADI trial, researchers found that extending adalimumab (ADA) dosing intervals was just as effective as standard dosing for Crohn's disease patients in remission.
- The study aimed to create a prediction model to identify patients who could successfully increase their dosing intervals based on trial data.
- Results showed that 60.6% of patients successfully extended their dosing, with certain factors (like smoking and prior surgeries) making success less likely; the model's effectiveness needs further external validation before clinical use.
Background: Despite recent emerging literature involving the utility of endoscopic balloon dilation (EBD) of strictures balloon-assisted endoscopy (BAE), specifically regarding the management of Crohn's disease (CD), the optimal clinical approach with balloon systems has been largely neglected in academic literature.
Objectives: This study assesses the intra-procedural success and safety of EBD BAE for small bowel CD strictures while detailing our clinical approach and technique. Secondarily, we compare the single-balloon endoscope (SBE) and double-balloon endoscope (DBE) systems for EBD-related outcomes.
Article Synopsis
- Canada is facing a significant burden of inflammatory bowel disease (IBD), with an estimated incidence of 29.9 per 100,000 in 2023, and a stable increase forecasted to 31.2 per 100,000 by 2035.
- Pediatric cases are on the rise with an average annual percentage change (AAPC) of 1.27%, while the incidence among adults remains stable with an AAPC of 0.26%.
- The prevalence of IBD is projected to increase from 843 per 100,000 in 2023 to 1,098 per 100,000 by 2035, particularly affecting seniors, who have the highest prevalence rate.
Background And Aims: We explored the potential for differential efficacy of vedolizumab between early and late ulcerative colitis [UC] with evaluation of clinical, endoscopic, and histological endpoints.
Methods: This was a multicentre, multinational, open-label study in patients with moderately-to-severely active UC, defining early UC by a disease duration <4 years and bio-naïve and late UC by a disease duration > 4 years and additional exposure to tumour necrosis factor antagonists. Patients received standard treatment with intravenous vedolizumab for 52 weeks [300 mg Weeks 0, 2, 6, every 8 weeks thereafter without escalation].
Purpose: Recently, recommendations on perioperative care have been published to optimize postoperative outcomes in preoperative patients with inflammatory bowel disease. This study evaluated the current use of preoperative screening and prehabilitation strategies (PS) prior to elective ileocolic resection (ICR) in patients with Crohn's disease (CD).
Methods: Patients with CD who underwent an elective ICR were identified from a Dutch prospective cohort study.
Background: The advantage of early ileocecal resection after Crohn's disease diagnosis is a matter of debate. This study aims to assess the timing of ileocecal resection on prognosis, after correction for possible confounders.
Methods: Patients with Crohn's disease with primary ileocecal resection between 2000 and 2019 were included in a retrospective multicentre cohort.
Introduction: The prognostic value of the modified Rutgeerts score (mRS) in patients with Crohn's disease (CD) needs to be further elucidated. This study assessed the prognostic value of the mRS for long-term outcomes after primary ileocecal resection in patients with CD.
Methods: Patients with CD after primary ileocecal resection with an available mRS at first postoperative ileocolonoscopy (index mRS) were retrospectively included.
Background And Aim: Patients with inflammatory bowel disease (IBD) treated with thiopurines are at increased risk of keratinocyte skin cancer (KSC). Most international guidelines recommend yearly dermatological screening of thiopurine-treated patients. Whether the association between the development of KSC and the use of thiopurines is dose-dependent remains unclear.
View Article and Find Full Text PDFSmoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship.
United European Gastroenterol J
September 2023
Background And Aims: Prior studies on the effect of smoking on the risk of colitis-associated colorectal neoplasia (CRN) have reported conflicting results. We aimed to further elucidate the association between smoking, including possible dose-effects, and the development of colorectal neoplasia in patients with inflammatory bowel disease (IBD).
Methods: We performed a prospective multicenter cohort study including patients with colonic IBD enrolled in a surveillance program in four academic hospitals between 2011 and 2021.
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study.
Eur J Drug Metab Pharmacokinet
July 2023
Article Synopsis
- Adalimumab underdosing can lead to ineffective treatment for rheumatic and inflammatory bowel diseases, prompting a study to forecast its concentrations early in therapy using population pharmacokinetic modeling.
- A literature search identified pharmacokinetic models, and patient samples were analyzed to predict steady state levels of adalimumab after the first dose, evaluating predictive performance through error metrics.
- The study included 36 patients, showing a 75% concordance between predicted and actual drug levels, and confirmed that early measurements can effectively predict future drug concentrations during treatment initiation.
Article Synopsis
- The study aimed to evaluate the cost-effectiveness of lengthening adalimumab dosing intervals for patients with Crohn's disease who are in stable remission, compared to the standard two-week interval.
- A total of 174 patients participated, with results showing no significant difference in overall quality of life and total costs between the extended interval and control groups, although medication costs were lower in the extended group.
- Increased dosing intervals were deemed cost-effective if the value of a quality-adjusted life year is below €53,960, suggesting that for higher valuations, the conventional dosing remains more favorable.
Background: Inflammatory bowel disease (IBD) patients are at increased risk of advanced neoplasia (high-grade dysplasia or colorectal cancer). The authors aimed to (1) assess synchronous and metachronous neoplasia following (sub)total or proctocolectomy, partial colectomy or endoscopic resection for advanced neoplasia in IBD, and (2) identify factors associated with treatment choice.
Material And Methods: In this retrospective multicenter cohort study, the authors used the Dutch nationwide pathology databank (PALGA) to identify patients diagnosed with IBD and colonic advanced neoplasia (AN) between 1991 and 2020 in seven hospitals in the Netherlands.
Background And Aims: Colonic bacterial biofilms are frequently present in ulcerative colitis [UC] and may increase dysplasia risk through pathogens expressing oncotraits. This prospective cohort study aimed to determine [1] the association of oncotraits and longitudinal biofilm presence with dysplasia risk in UC, and [2] the relation of bacterial composition with biofilms and dysplasia risk.
Methods: Faeces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls.
Background: Women with inflammatory bowel disease (IBD) are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+).
Aim: To assess the association between cumulative exposure to immunomodulators (IM) and biologic agents (BIO) for IBD and CIN2+ METHODS: Adult women diagnosed with IBD before December 31st 2016 in the Dutch IBD biobank with available cervical records in the nationwide cytopathology database were identified. CIN2+ incidence rates in IM- (i.
Background: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs that require therapy adjustment beyond 12 months of treatment are rare.
Aim And Methods: This single-center prospective cohort study evaluated the safety of a reduced 6-monthly monitoring strategy in steroid-free patients with quiescent IBD on stable dose of azathioprine, mercaptopurine, or thioguanine monotherapy.
Background: Fatigue is a common problem in immune-mediated inflammatory disease (IMID) patients, significantly impacting their quality of life.
Objectives: In this study, we describe the pattern and characteristics of fatigue as a patient-reported adverse drug reaction (ADR) of biologics, and compared patient and treatment characteristics with patients reporting other ADRs or no ADRs.
Methods: In this cohort event monitoring study, the description and characteristics of fatigue reported as a possible ADR in the Dutch Biologic Monitor were assessed and analysed for commonly recurring themes or patterns.
Objective: It is unknown whether ustekinumab (UST) levels can predict clinical outcomes in Crohn's disease (CD) patients. We assessed the exposure-response relationship of UST trough concentrations with biochemical outcomes at week 24 in a prospective, real-world setting.
Methods: We performed a prospective study in patients with CD starting UST in four academic centres in the Netherlands.
Article Synopsis
- A study examined sex differences in adverse drug reactions (ADRs) reported by patients with inflammatory rheumatic diseases, focusing on those using etanercept or adalimumab.
- A total of 748 patients participated, revealing that 55% of women reported at least one ADR compared to 38% of men, with significant differences in the types of ADRs reported.
- While women reported more injection site reactions, the overall burden of ADRs was similar between sexes, highlighting important considerations for clinical counseling and ADR investigations.